Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up.
Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview.
“Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said, adding that developing a...
Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital
Global - Asia
•
November 17, 2026
•
4 views
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



